Cell and Gene Overexpression Service Companies and Market Trends Analysis

Which are the Top Companies in the Market?

• GenScript Biotech
• Charles River Laboratories
• Lonza Group
• WuXi AppTec
• Thermo Fisher Scientific
• Creative Biogene
• VectorBuilder
• Vigene Biosciences (Charles River)
• OriGene Technologies
• Addgene
• Takara Bio
• Eurofins Scientific
• BioIVT
• Cyagen Biosciences
• Evotec SE
• Horizon Discovery (PerkinElmer)
• Sangamo Therapeutics (Service Division)
• Miltenyi Biotec
• Cobra Biologics (Charles River)
• SBI System Biosciences

Market Growth

The global cell and gene overexpression service market size is calculated at US$ 771.40 million in 2024, grew to US$ 805.73 million in 2025, and is projected to reach around US$ 1,192.24 million by 2034. The market is expanding at a CAGR of 4.45% between 2025 and 2034.

Market Value Chain Analysis

R&D

With the use of advanced technologies such as refined CRISPR-based gene editing, next-generation vectors, etc., the precision, efficiency, and safety of genetic material expression and delivery will be enhanced in the R&D of cell and gene overexpression services.

Key Players: Vertex Pharmaceuticals, CRISPR Therapeutics, Novartis, Gilead Sciences.

Clinical Trials and Regulatory Approvals

The dosage, safety, and efficacy will be monitored for clinical trial approvals, while risk-benefit profiles, manufacturing quality, and clinical benefits will be the focus for the regulatory approvals for the cell and gene overexpression services.

Key Players: Gilead Sciences, CRISPR Therapeutics, Novartis, Bluebird Bio.

Patient Support and Services

The patient support and services for cell and gene overexpression services focus on offering comprehensive care while addressing the complex emotional, educational, financial, and logistical needs of the patient throughout their treatment.

Key Players: Novartis, Sarepta Therapeutics, Gilead Sciences.

Latest Announcements by Industry Leaders

In January 2025, after the launch of RASTRUMTM Allegro, the Founder and CEO of Inventia Life Science, Julio Ribeiro, stated that, for advancing the work, the scientists are well-versed with the value of biologically relevant models. For better representation of human biology, they have developed RASTRUM Allegro, which will provide researchers with the ability to generate complex 3D cell models. To propel the discovery and uncover deeper biological insights, the scalability and precision will be offered by this system.

What are the Recent Developments in the Market?

• In August 2025, Merck became the first CDMO and technology developer to offer a full viral vector manufacturing, including Lentiviral, AAV, process development, CDMO, and CTO, by launching VirusExpress® 293 Adeno-Associated Virus (AAV) production platform. The speed of clinical manufacturing will be enhanced, along with minimizing the cost and process development time, by this platform.
• In May 2025, a collaboration between Genenta Science and Anemocyte was announced. This collaboration will focus on the production of critical starting materials, such as the manufacturing of Plasmids for viral vector production and the establishment of Cell Banks, achieving a milestone and advancing in immuno-oncology therapies.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com